Celldex Therapeutics

(NASDAQ) CLDX

Current Price$32.10

Market Cap$2.61B

Since IPO (2008)-71%

5 Year+6%

1 Year+54%

1 Month+9%

Celldex Therapeutics Financials at a Glance

Market Cap

$2.61B

Revenue (TTM)

$1.50M

Net Income (TTM)

$258.80M

EPS (TTM)

$-3.90

P/E Ratio

-8.53

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$32.10

Volume

602,775.74

Open

$32.73

Price

$32.10

Volume

602,775.74

Open

$32.73

Previous Close

$32.14

Daily Range

$31.65 - $33.04

52-Week Range

$17.85 - $35.79

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$32.10

Volume

602,775.74

Open

$32.73

Previous Close

$32.14

Daily Range

$31.65 - $33.04

52-Week Range

$17.85 - $35.79

CLDX News

Celldex Therapeutics SVPs Engage In Heavy Transactions

Adé HennisJan 12, 2026

Two people seated at a lab desk featuring a PC screen and microscope

Page 1

CLDX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celldex Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

198

CEO

Anthony S. Marucci, MBA

Website

www.celldex.com

Headquarters

Hampton, NJ 08827, US

CLDX Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-192%

Net Income Margin

-173%

Return on Equity

-41%

Return on Capital

-54%

Return on Assets

-44%

Earnings Yield

-11.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.61B

Shares Outstanding

78.46M

Volume

602.78K

Avg. Volume

1.04M

Financials (TTM)

Gross Profit

$1.50M

Operating Income

$287.40M

EBITDA

$255.42M

Operating Cash Flow

$210.94M

Capital Expenditure

$2.71M

Free Cash Flow

$213.66M

Cash & ST Invst.

$518.57M

Total Debt

$2.34M

Celldex Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$75.00K

-93.6%

Gross Profit

$75.00K

-78.9%

Gross Margin

100.00%

N/A

Market Cap

$2.61B

N/A

Market Cap/Employee

$14.02M

N/A

Employees

186

N/A

Net Income

$81.36M

-72.8%

EBITDA

$80.54M

-45.9%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$516.24M

-28.4%

Accounts Receivable

$2.02M

+187.9%

Inventory

$0.00

N/A

Long Term Debt

$784.00K

-66.8%

Short Term Debt

$1.55M

+6.9%

Return on Assets

-44.39%

N/A

Return on Invested Capital

-54.02%

N/A

Free Cash Flow

$64.93M

-95.4%

Operating Cash Flow

$63.94M

-96.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VERAVera Therapeutics, Inc.

VERAVera Therapeutics, Inc.$35.84-3.42%

IMNMImmunome, Inc.

IMNMImmunome, Inc.$22.95-3.21%

HRMYHarmony Biosciences Holdings, Inc.

HRMYHarmony Biosciences Holdings, Inc.$31.05-0.35%

SIONSionna Therapeutics, Inc.

SIONSionna Therapeutics, Inc.$37.43-5.46%

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$4.34-4.82%

ABCLAbCellera Biologics Inc.

ABCLAbCellera Biologics Inc.$3.82-8.28%

QUREuniQure N.V.

QUREuniQure N.V.$16.73-7.31%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$94.75+0.12%

SOFISoFi Technologies

SOFISoFi Technologies$15.53-0.15%

NOKNokia

NOKNokia$12.46+0.10%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.14+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.86+0.02%

KALVKalVista Pharmaceuticals

KALVKalVista Pharmaceuticals$26.67+0.39%

POETPoet Technologies

POETPoet Technologies$6.60-0.18%

Questions About CLDX

What is the current price of Celldex Therapeutics?

Celldex Therapeutics is trading at $32.14 per share.

What is the 52-week range for Celldex Therapeutics?

Over the past 52 weeks, Celldex Therapeutics has traded between $17.85 and $35.79.

How much debt does Celldex Therapeutics have?

As of the most recent reporting period, Celldex Therapeutics reported total debt of $2.34M.

How much cash does Celldex Therapeutics have on hand?

Celldex Therapeutics reported $28.87M in cash and cash equivalents in its most recent financial results.

What is Celldex Therapeutics’s dividend yield?

Celldex Therapeutics does not currently have a dividend yield.

Celldex Therapeutics

Celldex Therapeutics Financials at a Glance

CLDX News

Celldex Therapeutics SVPs Engage In Heavy Transactions

Why Celldex Therapeutics Blasted 13% Higher on Monday

How Good Were Celldex Therapeutics' Latest Clinical Results?

Why Celldex Therapeutics Stock Is Jumping Again Today

Why Celldex Therapeutics Stock Is Skyrocketing Today

Could Celldex Be a Millionaire-Maker Stock?

Why Celldex Therapeutics Stock Is Tanking Today

2 Biotech Stocks That Keep on Climbing

CLDX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Celldex Therapeutics

CLDX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Celldex Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CLDX

What is the current price of Celldex Therapeutics?

What is the 52-week range for Celldex Therapeutics?

How much debt does Celldex Therapeutics have?

How much cash does Celldex Therapeutics have on hand?

What is Celldex Therapeutics’s dividend yield?

Premium Investing Services